ELTP Stock Current Trading Information 05/03/2014 23:48:42

New Post Public Reply Private Reply Replies (0) Message Board

May 4, 2014 at 12:48 AM

Friday Elite Pharma Inc (ELTP) $ELTP opened at 0.4715 hitting the high price of 0.4715 and a day low of 0.4310 with a total volume of 1,398,100. ELTP had a previous close of 0.4600 and has been seeing an average volume of 2,543,485.

Overall Average: 48% Buy

Recent stock forum discussions about ELTP http://investorshangout.com/search?q=ELTP&...mp;yt0=Go!

Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ -- (full story)

FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment
ACCESSWIRE - Tue Apr 29, 9:05AM CDT
BrainStorm Cell Therapeutics' (OTCQB: BCLI) stock volume skyrocketed Apr. 28, with 3,714,379 shares changing hands, more than 5 times its three-month average volume of 718,105 shares. (full story)

Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Apr 22, 6:41AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe. (full story)

Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners
ACCESSWIRE - Wed Apr 16, 9:07AM CDT
Limitless Venture Group Inc.'s (OTCPINK: LVGI) announced that the company and a third- party debt holder Beaufort Capital Partners reached an amicable settlement regarding an outstanding note which had essentially floorless convertible terms attached. (full story)

Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"

, a Chicago-based institutional investor for up to $40 million. (full story)

Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"

, a Chicago-based institutional investor for up to $40 Million. Proceeds from the transaction will be used to develop the Company's pipeline of products, including the abuse resistant opioids, and for general corporate purposes. (full story)

Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer. (full story)

OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com (full story)

Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility. (full story)

Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility. (full story)

Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY (full story)

Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada. (full story)

Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe. (full story)

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions. (full story)

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

("Elite"

(OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions. (full story)

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
GlobeNewswire - Fri Feb 14, 8:49AM CST
Revenues Increase by 154%, Product Development Accelerating (full story)

Prolexic Publishes Infographic on Largest Attacks Mitigated in 2013
M2 - Fri Feb 14, 8:07AM CST
Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today published a new infographic summarizing the statistics about the largest DDoS attacks it mitigated in each quarter of 2013. (full story)

Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
GlobeNewswire - Mon Feb 10, 2:27PM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Tuesday, February 18, 2014. Company executives will also conduct a question and answer session following their remarks. (full story)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lektra Unveils EdgeStart: Green Earnings from AI

AI and Solar Power: A New Revenue Stream Lektra's fresh off the blocks with EdgeStart, an AI server pushing building owners to make a buck off their idle solar power. These self-contained, 8-GPU NVIDIA cabinets don't just sit pretty; they’re money-makers, potentially turning an overlooked asset into a goldmine. If your building's solar panels are just loafing about...

Kyungtz'e Eosan Sooryukje: Honoring Spirits and History

An Enchanting Ritual Comes to NYC Some things transcend the humdrum of everyday life, and right now, New York's set to witness exactly that. It's not every day you get treated to Korea's deep-rooted Buddhist traditions, but come November 13 and 14, that's precisely what's in store. The Korean Cultural Center New York (KCCNY) is bringing Kyungtz'e Eosan Sooryukje to the...

Set Hach: A Leader Transforming Agrifood Systems

From Humble Beginnings to Global Recognition When a name like Set Hach doesn't just echo within local circles but reaches the global stage, you know something transformative is brewing. Here we have a woman celebrated as one of the 100 Women Heroes in Agrifood Systems by the UN Food and Agriculture Organization (FAO). Recognition like this speaks volumes, especially...

Compal and ARC Cloud Forge AI Partnership

AI Infrastructure: A New Era of Collaboration Well, here's one that's got my old trader veins throbbing with excitement. Compal Electronics and ARC Cloud are shaking hands in a deal that could sketch out a bold new chapter in AI infrastructure. This ain't your run-of-the-mill tech announcement; it's a strategic dance aimed at supercharging the very backbone of large-scale...

Piramal Pharma FY27 Q2 Results: Robust Growth & Optimism

A Solid Performance from Piramal Pharma The numbers are in, and it's looking pretty good for Piramal Pharma Limited this time around. Their second quarter of fiscal year 2027 has seen some fireworks, and I'm not talking about some half-baked confetti deal. We're talking genuine growth and solid metrics here. Revenue and Profit Surge The headline? Revenue jumped a whopping...

Right Heart Failure Gains Recognition as Its Own Syndrome

Changing the Narrative on Right Heart Failure How often do we see right heart failure (RHF) brushed aside like some understudy in the grand play of cardiovascular disease? Far too often, according to the Heart Failure Society of America (HFSA). They're here to shift that narrative, demanding RHF be recognized for what it truly is: a distinct clinical syndrome. Forget...

Ultrasound Innovations: 2D, 3D, and 4D Explained

Diving into the World of Ultrasound Imaging When you're in the trenches of expecting a new family member, the last thing you want is to get bogged down in technical jargon that doesn't make a lick of sense. Enter prenatal ultrasound imaging: 2D, 3D, and 4D. Each of these has a specific role in piecing together the puzzle of fetal development. Now, Erika Lambright, a...

Steel Vet Shift: John Pritchett Takes Helm at Trojan

Trojan Steel's Bold Move with John Pritchett at the Helm Trojan Steel is changing the game by appointing John C. Pritchett as its new President. This isn't just another shuffle of suits in the boardroom—it's a statement. Pritchett isn't some steel industry old-timer; instead, he's a business leader with a knack for scaling operations. With a resume that includes...

BNY's Conference Spotlight: Strategic Moves Ahead?

BNY's CFO to Unpack Strategies at BMO Financials Conference They say you can tell a lot about a company by the folks steering the ship. And let me tell you, folks, Dermot McDonogh from BNY is setting sail over to Boca Raton to spill some beans. November 9 marks the date when BNY’s Chief Financial Officer will stand behind the mic at the BMO Financials Conference at 8:45...

Americans' Faith in Democracy Hits New Lows

Polarization Beyond Politics: A National Reckoning When you catch wind of a report like this one, it's enough to make you feel like the fabric of democracy is unraveling right before our eyes. We're staring at a national identity crisis, folks, and it's got nothing to do with whether you're waving a red or blue flag. This ain't about party lines; it's about a bigger,...